Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism

Bitget2026/10/14 20:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Rezolute completed enrollment of 16 participants in its Phase 3 upLIFT trial of ersodetug for tumor hyperinsulinism.
Topline results are expected in mid-December 2026.
Previously reported results showed seven of the first eight participants met the primary endpoint; all seven stopped intravenous glucose treatment.
No drug-related safety findings have been reported in the study so far.
The eighth participant died from cancer progression shortly after enrollment and was counted as a nonresponder.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rezolute Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610141605PRIMZONEFULLFEED9845915) on October 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Rezolute Completes Enrollment in Phase 3 Ersodetug Trial for Tumor Hyperinsulinism

You may also like

Crypto prices